Citations

Showing 10 of 108083 citations.

Both HIV-Infected and Uninfected Cells Express TRAILshort, Which Confers TRAIL Resistance upon Bystander Cells within the Microenvironment
Nie, Zilin , Aboulnasr, Fatma, Natesampillai, Sekar, Burke, Stephen , Krogman, Ashton , Bren, Gary D., Chung, Thomas D.Y. , Anderson, J. , Smart, Michele, Katzmann, David J. , Rajagopalan, Govindarajan, Badley, Andrew D. , Burke, Stephen P , Anderson, Jeff R , Smart, Michele K, Cummins, Nathan W , Badley, Andrew D , Cummins, Nathan W.

Mayo Clinic

The Journal of Immunology | December 20, 2017 | Volume: 200 | Issue: 3 | Pages: 1110-1123

10.4049/jimmunol.1701113 | PMID 29263214 Get It

Abstract TNF-related apoptosis-inducing ligand (TRAIL) was initially described to induce apoptosis of tumor cells and/or virally infected cells, although sparing normal cells, and has been implicated in the pathogenesis of HIV disease. We previously identified TRAILshort, a TRAIL splice variant, in HIV-infected patients and characterized it as being a dominant negative ligand to subvert TRAIL-mediated killing. Herein, using single-cell genomics we demonstrate that TRAILshort is produced by HIV-infected cells, as well as by uninfected bystander cells, and that the dominant stimulus which induces TRAILshort production are type I IFNs and TLR7, TLR8, and TLR9 agonists. TRAILshort has a short t1/2 by virtue of containing a PEST domain, which targets the protein toward the ubiquitin proteasome pathway for degradation. Further we show that TRAILshort binds preferentially to TRAIL receptors 1 and 2 with significantly reduced interaction with the decoy TRAIL receptors 3 and 4. Recombinant TRAILshort is sufficient to protect cells against TRAIL-induced killing, whereas immunodepletion of TRAILshort with a specific Ab restores TRAIL sensitivity. Importantly we show that TRAILshort is shed in microvesicles into the cellular microenvironment and therefore confers TRAIL resistance not only on the cell which produces it, but also upon neighboring bystander cells. These results establish a novel paradigm for understanding and overcoming TRAIL resistance, in particular how HIV-infected cells escape immune elimination by the TRAIL:TRAILshort receptor axis.
Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer
He, Yundong , Ji, Lu , Ye, Zhenqing, Hao, Siyuan , Wang, Liewei , Wang, Liewei, Tindall, Donald J., Li, Benyi, Zhu, Runzhi, Wang, Liguo , Lu, Ji, Kohli, Manish , Wang, Liguo , Huang, Haojie

Mayo Clinic

Nucleic Acids Research | December 20, 2017 | Volume: 46 | Issue: 4 | Pages: 1895-1911

10.1093/nar/gkx1306 | PMID 29309643 Get It

Update in Hospital Palliative Care: Symptom Management, Communication, Caregiver Outcomes, and Moral Distress
Havyer, Rachel D. , Pomerantz, Daniel, Jayes, Robert L., Harris, Patricia F. , Ansari, Aziz , Harman, Stephanie M.

Mayo Clinic

Journal of Hospital Medicine | December 20, 2017 | Volume: 13 | Issue: 6 | Pages: 419-423

10.12788/jhm.2895 | PMID 29261818 Get It

BACKGROUNDUpdated knowledge of the palliative care (PC) literature is needed to maintain competency and best address the PC needs of hospitalized patients. We critiqued the recent PC literature with the highest potential to impact hospital practice.METHODSWe reviewed articles published between January 2016 and December 2016, which were identified through a handsearch of leading journals and a MEDLINE search. The final 9 articles selected were determined by consensus based on scientific rigor, relevance to hospital medicine, and impact on practice.RESULTSKey findings include the following: scheduled antipsychotics were inferior to a placebo for nonterminal delirium; a low‐dose morphine was superior to a weak opioid for moderate cancer pain; methadone as a coanalgesic improved high‐intensity cancer pain; many hospitalized patients on comfort care still receive antimicrobials; video decision aids improved the rates of advance care planning (ACP) and hospice use and decreased costs; standardized, PC‐led intervention did not improve psychological outcomes in families of patients with a chronic critical illness; caregivers of patients surviving a prolonged critical illness experienced high and persistent rates of depression; people with non‐normative sexuality or gender faced additional stressors with partner loss; and physician trainees experienced significant moral distress with futile treatments.CONCLUSIONSRecent research provides important guidance for clinicians caring for hospitalized patients with serious illnesses, including symptom management, ACP, moral distress, and outcomes of critical illness.
Faculty Opinions recommendation of The lifespan and turnover of microglia in the human brain.
Wu, Long‐Jun , Eyo, Ukpong B

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | December 20, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.727841009.793540552 Get It

Advances in Brain Tumor Surgery for Glioblastoma in Adults
Lara‐Velazquez, Montserrat , Al‐kharboosh, Rawan , Jeanneret, Stéphanie , Vazquez-Ramos, Carla , Mahato, Deependra, Tavanaiepour, Daryoush , Rahmathulla, Gazanfar , Quiñones‐Hinojosa, Alfredo

Mayo Clinic

Brain Sciences | December 20, 2017 | Volume: 7 | Issue: 12 | Pages: 166

10.3390/brainsci7120166 | PMID 29261148 Get It

Glioblastoma (GBM) is the most common primary intracranial neoplasia, and is characterized by its extremely poor prognosis. Despite maximum surgery, chemotherapy, and radiation, the histological heterogeneity of GBM makes total eradication impossible, due to residual cancer cells invading the parenchyma, which is not otherwise seen in radiographic images. Even with gross total resection, the heterogeneity and the dormant nature of brain tumor initiating cells allow for therapeutic evasion, contributing to its recurrence and malignant progression, and severely impacting survival. Visual delimitation of the tumor’s margins with common surgical techniques is a challenge faced by many surgeons. In an attempt to achieve optimal safe resection, advances in approaches allowing intraoperative analysis of cancer and non-cancer tissue have been developed and applied in humans resulting in improved outcomes. In addition, functional paradigms based on stimulation techniques to map the brain’s electrical activity have optimized glioma resection in eloquent areas such as the Broca’s, Wernike’s and perirolandic areas. In this review, we will elaborate on the current standard therapy for newly diagnosed and recurrent glioblastoma with a focus on surgical approaches. We will describe current technologies used for glioma resection, such as awake craniotomy, fluorescence guided surgery, laser interstitial thermal therapy and intraoperative mass spectrometry. Additionally, we will describe a newly developed tool that has shown promising results in preclinical experiments for brain cancer: optical coherence tomography.
Eosinophils promote inducible NOS–mediated lung allograft acceptance
Onyema, Oscar Okwudiri , Guo, Yizhan , Stoler, Mark H. , Lau, Christine L. , Li, Kang , Nazaroff, Christopher D. , Wang, Xingan , Kreisel, Daniel , Lee, James J. , Jacobsen, Elizabeth A. , Krupnick, Alexander S. , Nazaroff, Christopher Daniel, Jacobsen, Elizabeth A , Wang, Qing, Li, Wenjun , Gelman, Andrew E

Mayo Clinic

JCI Insight | December 20, 2017 | Volume: 2 | Issue: 24 | Pages: No page available

10.1172/jci.insight.96455 | PMID 29263310 Get It

Lungs allografts have worse long-term survival compared with other organ transplants. This is most likely due to their unique immunoregulation that may not respond to traditional immunosuppression. For example, local NO generation by inducible NOS (iNOS) is critical for lung allograft acceptance but associates with rejection of other solid organs. The source of NO in accepting lung allografts remains unknown. Here, we report that, unlike the case for other pulmonary processes in which myeloid cells control NO generation, recipient-derived eosinophils play a critical and nonredundant role in iNOS-mediated lung allograft acceptance. Depletion of eosinophils reduces NO levels to that of recipients with global deletion of iNOS and leads to a costimulatory blockade–resistant form of rejection. Furthermore, NO production by eosinophils depends on Th1 polarization by inflammatory mediators, such as IFN-γ and TNF-α. Neutralization of such mediators abrogates eosinophil suppressive capacity. Our data point to what we believe to be a unique and previously unrecognized role of eosinophil polarization in mediating allograft tolerance and put into perspective the use of high-dose eosinophil-ablating corticosteroids after lung transplantation.
Synectin promotes fibrogenesis by regulating PDGFR isoforms through distinct mechanisms
Drinane, Mary , Yaqoob, Usman , Yu, Haibin , Luo, Fanghong , Greuter, Thomas , Kostallari, Enis , Verma, Vikas , Assuncao, Thiago M. de , Kisseleva, Tatiana , Lomberk, Gwen , Gao, Yandong , Ligresti, Giovanni , Tschumperlin, Daniel J. , Revzin, Alexander , Cao, Sheng , Shah, Vijay H. , Drinane, Mary C, Arab, Juan P, Verma, Vikas K, Maiers, Jessica, De Assuncao, Thiago Milech, Urrutia, Raúl , Lomberk, Gwen L , Kostallari, Enis , Yaqoob, Usman , Arab, Juan Pablo , Maiers, Jessica L. , Simons, Michael , Mukhopadhyay, Debabrata , Brenner, David A.

Mayo Clinic

JCI Insight | December 20, 2017 | Volume: 2 | Issue: 24 | Pages: No page available

10.1172/jci.insight.92821 | PMID 29263300 Get It

The scaffold protein synectin plays a critical role in the trafficking and regulation of membrane receptor pathways. As platelet-derived growth factor receptor (PDGFR) is essential for hepatic stellate cell (HSC) activation and liver fibrosis, we sought to determine the role of synectin on the PDGFR pathway and development of liver fibrosis. Mice with deletion of synectin from HSC were found to be protected from liver fibrosis. mRNA sequencing revealed that knockdown of synectin in HSC demonstrated reductions in the fibrosis pathway of genes, including PDGFR-β. Chromatin IP assay of the PDGFR-β promoter upon synectin knockdown revealed a pattern of histone marks associated with decreased transcription, dependent on p300 histone acetyltransferase. Synectin knockdown was found to downregulate PDGFR-α protein levels, as well, but through an alternative mechanism: protection from autophagic degradation. Site-directed mutagenesis revealed that ubiquitination of specific PDGFR-α lysine residues was responsible for its autophagic degradation. Furthermore, functional studies showed decreased PDGF-dependent migration and proliferation of HSC after synectin knockdown. Finally, human cirrhotic livers demonstrated increased synectin protein levels. This work provides insight into differential transcriptional and posttranslational mechanisms of synectin regulation of PDGFRs, which are critical to fibrogenesis.
Decreased Expression of Sulfatase 2 in the Brains of Alzheimer’s Disease Patients: Implications for Regulation of Neuronal Cell Signaling
Roberts, Rosebud O., Kang, Yoo Na , Moser, Catherine D., Wang, Shaoqing , Moore, Michael J. , Lai, Jinping , Petersen, Ronald C. , Roberts, Lewis R. , Chen, Chen , Lai, Jin-Ping, Chen, C , Roberts, Lewis R , Hu, Chunling , Moore, Michael J. B. , Graham, Rondell P.

Mayo Clinic

Journal of Alzheimer's Disease Reports | December 20, 2017 | Volume: 1 | Issue: 1 | Pages: 115-124

10.3233/adr-170028 | PMID 30035253 Get It

Background: The human sulfatase 1 (SULF1) and sulfatase 2 (SULF2) genes modulate cell signaling and homeostasis in many tissues. Gene expression analyses have implicated SULF2 in disease pathogenesis, including Alzheimer’s disease (AD), but changes in brain SULF2 expression have not been directly established. Objective: To investigate the expression of SULF1 and SULF2 in brain tissues from AD cases and cognitively normal controls. Methods: Autopsy tissue from AD cases ( n = 20) and age-and gender-matched cognitively normal controls ( n = 20) were identified from the Mayo Clinic Alzheimer’s Disease Patient Registry neuropathology database. Tissue slides were stained for SULF1 and SULF2 protein expression in the hippocampus and frontal lobe and an expression score computed from the proportion of cells stained and the intensity of staining (range 0 [no expression] to 9 [marked expression]). Results: SULF2 expression was reduced in AD cases. Compared to cognitively normal controls, SULF2 expression in AD cases was significantly decreased in the hippocampal Cornu Ammonis (CA) (mean score of 6.5 in cases versus 8.3 in controls; p = 0.003), in the gray matter of the parahippocampal gyrus (5.6 in cases versus 7.6 in controls; p = 0.003), and in the frontal lobe gray matter (5.4 in cases versus 7.4 in controls; p = 0.002). There was no difference in SULF1 expression in the hippocampus or frontal lobe of AD cases and controls. As expected there were no differences in SULF1 or SULF2 expression in white matter in AD cases compared to cognitively normal controls. Conclusion: Decreased SULF2 in specific regions of the brain occurs in AD.
A phase I/II trial of vorinostat (SAHA) in combination with rituximab‐CHOP in patients with newly diagnosed advanced stage diffuse large B‐cell lymphoma (DLBCL): SWOG S0806
Persky, Daniel O. , Popplewell, Leslie , Bane, Charles, Gehr, Ann Von, Fisher, Richard I., Smith, Sonali M. , Friedberg, Jonathan W. , Popplewell, Leslie L , Li, Hongli , Rimsza, Lisa M. , Barr, Paul M. , LeBlanc, Michael

Mayo Clinic

American Journal of Hematology | December 20, 2017 | Volume: 93 | Issue: 4 | Pages: 486-493

10.1002/ajh.25010 | PMID 29266344 Get It

AbstractLoss of major histocompatibility Class II expression (MHCII) in diffuse large B‐cell lymphoma (DLBCL) correlates with decreased survival. MHCII transcription is in part regulated by histone acetylation. We tested the hypothesis that combination of histone deacetylase inhibitor (HDACI) with standard chemotherapy would improve outcomes in DLBCL in part through increased MHCII expression. S0806 was a single arm phase I/II trial of vorinostat given at 400 mg po daily on days 1‐9 (subsequently amended to days 1‐5 due to toxicity), combined with R‐CHOP given on day 3 of a 21‐day cycle for 8 cycles, with primary phase II endpoint of 2‐year progression free survival (PFS). With 72 evaluable patients, at median follow up of 3 years, 2‐year PFS estimate was 73%, and OS estimate was 86%. Considering that the regimen fell short of predefined efficacy improvement and was associated with high rates of febrile neutropenia (38%) and sepsis (19%), it cannot be recommended for general use. Consistent with our hypothesis, patients with low MCHII expression on S0806 had numerically superior outcomes compared to those from trial S0433 which did not use an HDACI, but the difference was not statistically significant. Current studies are focused on finding biomarkers of response to HDACI.